Skip to main content
NIH funding notice RFA-MH-20-325

Limited Competition: Consortium on Biomarker and Outcome Measures of Social Impairment for Use in Clinical Trials in Autism Spectrum Disorder (U19 Clinical Trial Not Allowed)

Closed on December 23, 2019.

Posted
November 6, 2019
Close date
December 23, 2019
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $7,995,717 in first-year total cost, median $7,995,717.

Most frequent study sections

  1. Special Emphasis Panel[ZMH1 ERB-G (05)]1

Most frequent institutions

  1. YALE UNIVERSITY1
Competing awards under RFA-MH-20-325 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2020The Autism Biomarkers Consortium for Clinical Trials2U19MH108206-05MCPARTLAND, JAMES CHARLESYALE UNIVERSITY, CT$7,995,717ZMH1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-MH-20-325: Limited Competition: Consortium on Biomarker and Outcome Measures of Social Impairment for Use in Clinical Trials in Autism Spectrum Disorder (U19 Clinical Trial Not Allowed) | ScienceDex | ConductScience